
|Articles|January 2, 2006
Endo provides more info on oxymorphone ER and IR tablets
Advertisement
Endo Pharmaceuticals has responded to the FDA's request for more information on the company's application for the investigational painkillers oxymorphone extended-release (ER) and immediate-release (IR) tablets. The FDA requested additional clinical trials to further confirm the safety and efficacy of the products after issuing approval letters in October 2003. If its product is approved, Endo said it's prepared to launch oxymorphone in the second half of 2006.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FAQ: The Medicare GLP-1 Bridge—What Independent Pharmacists Need to Know
2
Grocery Pharmacy Conglomerate to Pay $40 Million for Violating False Claims Act
3
Pharmacy Law Lowdown: GLP-1 Compounding
4
HHS Claims ACIP Cannot Meet for Flu Season Due to Ongoing Legal Battle
5



































